Genomic Landscape of Lung Adenocarcinoma in East Asians

Overview

Journal Nat Genet

Specialty Genetics

Date 2020 Feb 5

PMID 32015526

Citations 227

Authors

Jianbin Chen

Hechuan Yang

Audrey Su Min Teo

Lidyana Bte Amer

Faranak Ghazi Sherbaf

Chu Quan Tan

Jacob Josiah Santiago Alvarez

Bingxin Lu

Jia Qi Lim

Angela Takano

Rahul Nahar

Yin Yeng Lee

Cheryl Zi Jin Phua

Khi Pin Chua

Lisda Suteja

Pauline Jieqi Chen

Mei Mei Chang

Tina Puay Theng Koh

Boon-Hean Ong

Devanand Anantham

Anne Ann Ling Hsu

Apoorva Gogna

Chow Wei Too

Zaw Win Aung

Yi Fei Lee

Lanying Wang

Tony Kiat Hon Lim

Andreas Wilm

Poh Sum Choi

Poh Yong Ng

Chee Keong Toh

Wan-Teck Lim

Siming Ma

Bing Lim

Jin Liu

Wai Leong Tam

Anders Jacobsen Skanderup

Joe Poh Sheng Yeong

Eng-Huat Tan

Caretha L Creasy

Daniel Shao Weng Tan

Axel M Hillmer

Weiwei Zhai

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the world's leading cause of cancer death and shows strong ancestry disparities. By sequencing and assembling a large genomic and transcriptomic dataset of lung adenocarcinoma (LUAD) in individuals of East Asian ancestry (EAS; n = 305), we found that East Asian LUADs had more stable genomes characterized by fewer mutations and fewer copy number alterations than LUADs from individuals of European ancestry. This difference is much stronger in smokers as compared to nonsmokers. Transcriptomic clustering identified a new EAS-specific LUAD subgroup with a less complex genomic profile and upregulated immune-related genes, allowing the possibility of immunotherapy-based approaches. Integrative analysis across clinical and molecular features showed the importance of molecular phenotypes in patient prognostic stratification. EAS LUADs had better prediction accuracy than those of European ancestry, potentially due to their less complex genomic architecture. This study elucidated a comprehensive genomic landscape of EAS LUADs and highlighted important ancestry differences between the two cohorts.

Citing Articles

Distribution of and Mutations in Patients with Surgically Resected Non-Small Cell Lung Cancer from Southern Italy: Real-Life Data from a Single Institution and Literature Review.

Piazzolla M, Parente P, Centra F, Fabrizio F, Delcuratolo M, Centonza A Cancers (Basel). 2025; 17(5).

PMID: 40075579 PMC: 11899559. DOI: 10.3390/cancers17050730.

Multi-gene panel sequencing reveals the relationship between driver gene mutation and clinical characteristics in lung adenocarcinoma.

Li J, Li X, Guo H, Zhou S, Ding H, Li B Discov Oncol. 2025; 16(1):274.

PMID: 40053265 PMC: 11889310. DOI: 10.1007/s12672-025-02008-1.

Impact of histopathological subtypes on invasive lung adenocarcinoma: from epidemiology to tumour microenvironment to therapeutic strategies.

Xin S, Wen M, Tian Y, Dong H, Wan Z, Jiang S World J Surg Oncol. 2025; 23(1):66.

PMID: 40016762 PMC: 11866629. DOI: 10.1186/s12957-025-03701-9.

Integration of multiple machine learning approaches develops a gene mutation-based classifier for accurate immunotherapy outcomes.

Shi R, Sun J, Zhou Z, Shi M, Wang X, Gao Z NPJ Precis Oncol. 2025; 9(1):54.

PMID: 40011681 PMC: 11865301. DOI: 10.1038/s41698-025-00842-8.

Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in -Mutated Lung Adenocarcinoma.

Uehara Y, Izumi H, Taki T, Sakai T, Udagawa H, Sugiyama E JTO Clin Res Rep. 2025; 6(3):100779.

PMID: 40007550 PMC: 11850751. DOI: 10.1016/j.jtocrr.2024.100779.

References

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Cheng T, Cramb S, Baade P, Youlden D, Nwogu C, Reid M . The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J Thorac Oncol. 2016; 11(10):1653-71. PMC: 5512876. DOI: 10.1016/j.jtho.2016.05.021. View

Imielinski M, Berger A, Hammerman P, Hernandez B, Pugh T, Hodis E . Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150(6):1107-20. PMC: 3557932. DOI: 10.1016/j.cell.2012.08.029. View

Campbell J, Alexandrov A, Kim J, Wala J, Berger A, Pedamallu C . Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016; 48(6):607-16. PMC: 4884143. DOI: 10.1038/ng.3564. View

Kadara H, Choi M, Zhang J, Parra E, Rodriguez-Canales J, Gaffney S . Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol. 2016; 28(1):75-82. PMC: 5982809. DOI: 10.1093/annonc/mdw436. View

Garon E, Rizvi N, Hui R, Leighl N, Balmanoukian A, Eder J . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018-28. DOI: 10.1056/NEJMoa1501824. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara D, Aix S . Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018; 13(8):1156-1170. DOI: 10.1016/j.jtho.2018.04.039. View

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

10.

Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J . Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018; 362(6411). PMC: 6718162. DOI: 10.1126/science.aar3593. View

11.

Tan W, Jain A, Takano A, Newell E, Iyer N, Lim W . Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol. 2016; 17(8):e347-e362. DOI: 10.1016/S1470-2045(16)30123-1. View

12.

Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba I . Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97(5):339-46. DOI: 10.1093/jnci/dji055. View

13.

Jain A, Lim C, Gan E, Ng D, Ng Q, Ang M . Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. PLoS One. 2015; 10(5):e0123587. PMC: 4425557. DOI: 10.1371/journal.pone.0123587. View

14.

Kris M, Johnson B, Berry L, Kwiatkowski D, Iafrate A, Wistuba I . Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014; 311(19):1998-2006. PMC: 4163053. DOI: 10.1001/jama.2014.3741. View

15.

Wu K, Zhang X, Li F, Xiao D, Hou Y, Zhu S . Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. Nat Commun. 2015; 6:10131. PMC: 4682110. DOI: 10.1038/ncomms10131. View

16.

Wang C, Yin R, Dai J, Gu Y, Cui S, Ma H . Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients. Nat Commun. 2018; 9(1):2054. PMC: 5967326. DOI: 10.1038/s41467-018-04492-2. View

17.

Luo W, Tian P, Wang Y, Xu H, Chen L, Tang C . Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers. Int J Cancer. 2018; 143(7):1696-1705. PMC: 6175072. DOI: 10.1002/ijc.31542. View

18.

Nahar R, Zhai W, Zhang T, Takano A, Khng A, Lee Y . Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. Nat Commun. 2018; 9(1):216. PMC: 5768770. DOI: 10.1038/s41467-017-02584-z. View

19.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

20.

DePristo M, Banks E, Poplin R, Garimella K, Maguire J, Hartl C . A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011; 43(5):491-8. PMC: 3083463. DOI: 10.1038/ng.806. View